Infections After Prostate Biopsy Continue to Rise
Infectious complication rates following prostate biopsies continue to increase, despite decreased use of the procedures, a new study confirms.
Jim C. Hu, M.D., MPH, of Weill Cornell Medicine, and colleagues reported that the rates of infection within 30 days of prostate biopsy increased from 2.6% to 3.5% from 2011 to 2014 in New York State, based on data from patients of all ages and payment modalities. Complication rates were higher for transrectal than transperineal biopsies. Rates did not differ between initial and repeat biopsies.
Jim Hu, M.D. ~ Sharp drop in prostate cancer procedures after PSA screening curb (MDalert.com)
By David Douglas
NEW YORK (Reuters Health) - Since guidelines recommended a halt to population-based prostate specific antigen (PSA) screening, there has been a significant drop in the volume of prostate biopsy and radical prostatectomy, according to researchers.
The U.S. Preventive Services Task Force (USPSTF) recommended against routine PSA screening in 2012.
(MedScape with Dr. Hu) Big Drop in Prostate Biopsies, Prostatectomies in US
This is an excerpt from Medscape, featuring Dr. Jim Hu. Read the full text here.
Since the US Preventive Services Task Force (USPSTF) issued its recommendation against prostate-specific antigen (PSA) screening in 2012, the use of PSA screening and digital rectal examinations has decreased significantly, as has the incidence of early-stage prostate cancer.
(NBC News with Dr. Hu) Prostate Surgery Rates Fall After Screening Advice, Study Finds
Read article here : Prostate Surgery Rates Fall After Screening Advice, Study Finds
Dr. Hu speaks to NBC news about his recent publication in JAMA Surgery National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the United States Preventative Services Task Force Guidelines Against Prostate-Specific Antigen Screening
Significant decrease seen in prostate biopsy, radical prostatectomy procedures following recommendations
In a study published online by JAMA Surgery, Jim C. Hu, M.D., M.P.H., Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and colleagues examined effects on practice patterns in prostate cancer diagnosis and treatment following the U.S. Preventative Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA) screening in 2012.
Significant decrease seen in prostate biopsy, radical prostatectomy procedures following recommendations
In a study published online by JAMA Surgery, Jim C. Hu, M.D., M.P.H., Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and colleagues examined effects on practice patterns in prostate cancer diagnosis and treatment following the U.S. Preventative Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA) screening in 2012.
What does the future hold for robotics in medicine? (92Y Panel with Weill Cornell Medicine)
What does the future hold for robotics in medicine?
Medical experts from Weill Cornell Medicine discuss this fascinating topic. Joining us for this panel are Cheguevara Afaneh, MD; T. Sloane Guy, MD; Jim Hu, MD; Jeffrey Port, MD; Douglas Scherr, MD; and Joel Stein, MD, with moderator Dr. Max Gomez from WCBS-TV.
The past decade has produced tremendous advances in the use of robotics across clinical areas, vastly expanding the horizons of disease management.
Diagnosis and Treatment of Small Renal Masses - Jim C. Hu, MD, MPH
Dr. Jim C. Hu from Weill Cornell Medicine provides an overview on update on the risks & causes, diagnosis, and treatment options for kidney masses.
Update on Prostate Cancer Screening and Diagnosis - Jim C. Hu, M.D.
Dr. Jim C. Hu from Weill Cornell Medicine Urology provides an update and overview on the state-of-the-art management practices following an elevated PSA or diagnosis of prostate cancer.
Prostate cancer patients are paying hefty price for controversial new treatment
Read the full original article, featuring Dr. Jim C. Hu, on the PBS website here.
Men hoping to avoid some side effects of prostate cancer treatment are shelling out tens of thousands of dollars for a procedure whose long-term effects are unknown and insurers, including Medicare, won’t pay for.
